Medpace Reports Earnings Miss with Increased Cancellations Pressuring Stock
Apr 23, 2026, 2:46 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The significant drop in stock price indicates investor concern over future revenue due to cancellations and a bookings miss, reminiscent of past earnings responses when guidance is uncertain.
AI summary
What happened, with direct paths to the underlying reporting
Medpace Holdings, Inc. (MEDP) shares dropped 21.90% following their earnings report, where elevated cancellations in oncology and cardiovascular sectors created near-term revenue headwinds. While EPS and revenue surpassed estimates, the bookings miss and diminished visibility beyond two quarters have raised concerns among investors.
Sequential growth expected to be flat; visibility beyond two quarters is limited.
EPS and revenue exceeded estimates, but bookings missed expectations.
CEO highlighted M&A as a headwind, affecting future work.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Medpace posted Q2 results topping estimates with $4.25 earnings and $707.33 million in sales, up 17.2% YoY. Backlog rose to over $3.01 billion, with net-new awards of $795.7 milli…
Medpace reported Q3 earnings of $3.86, beating estimates of $3.52. Sales rose to $659.9 million, exceeding the $640.99 million consensus. Fiscal 2025 EPS guidance increased to $14…
Medpace's Q3 new orders surged 49% to $789 million. Revenue of $659.9 million exceeded analyst expectations significantly. Biotech sector shows signs of recovery, impacting Medpac…